Filing Flows › Mangoceuticals (MGRX) › Q2 2026 › vs Q2 2025
Mangoceuticals (MGRX) Q2 2026 vs Q2 2025 (year over year)
Mangoceuticals's revenue fell $99K (-59%) from $168K in Q2 2025 to $69K in Q2 2026.
Mangoceuticals, Q2 2026: revenue $69K (-59% year over year), net loss $1.3M, operating cash flow −$261K. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $69K | $168K | −$99K | -59% |
| Net loss | $1.3M | $5.4M | −$4.1M | -76% |
| Costs & expenses | $1.4M | $5.6M | −$4.2M | -75% |
| Operating costs | $1.1M | $5.4M | −$4.3M | -80% |
| Interest & other, net | $280K | $147K | $133K | +90% |
| Cost of revenue | $25K | $78K | −$54K | -69% |
| Sales & marketing | $301K | $258K | $43K | +17% |
| General & admin | $256K | $1.2M | −$989K | -79% |
| Other operating costs | $520K | $3.9M | −$3.3M | -87% |
| Operating cash sources | $1.3M | $5.4M | −$4.1M | -76% |
| Depreciation & amortization | $280K | $278K | $2K | +0.6% |
| Share-based compensation | $12K | $51K | −$39K | -76% |
| Working capital & other | $760K | $3.8M | −$3.1M | -80% |
| Cash used in operations | $261K | $1.3M | −$996K | -79% |
| Net loss absorbed | $1.3M | $5.4M | −$4.1M | -76% |
Questions
How much did Mangoceuticals's revenue grow year over year in Q2 2026?
Mangoceuticals's revenue fell $99K (-59%) from $168K in Q2 2025 to $69K in Q2 2026.